Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

in patients with unresectable hepatocellular carcinoma (HCC), according to results from the CARES-005 study. At a median follow-up of 13.6 months, the median PFS was 10.8 months with TACE plus ...

Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization ...

Results of CHANCE 2005/CARES-005 study were unveiled by Dr Gao-Jun Teng from Zhongda Hospital, Southeast University, China, ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Japanese researchers sought to build upon prior studies demonstrating the feasibility of liver resection in geriatric hepatocellular carcinoma patients, particularly in those undergoing major ...

Transarterial chemoembolization (TACE) is currently the most common approach for the management of hepatocellular carcinoma (HCC) without curative options. TACE consists of the injection of ...